21 – 30 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
-
Mark
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Letter
- 2016
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
- 2015
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
-
Mark
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.
(
- Contribution to journal › Article
- 2012
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
-
Mark
Genetically Distinct Subsets within ANCA-Associated Vasculitis
(
- Contribution to journal › Article
- 2011
-
Mark
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
(
- Contribution to journal › Article